SHENZHEN, CHINA, June 25, 2025 — China Medical System Holdings Limited (the “Company” and its subsidiaries, the “Group”) has announced its plan for a secondary listing of its ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (“SGX-ST”) through an introduction process (the “Proposed Secondary Listing”). If the Proposed Secondary Listing proceeds, it will not involve the issuance of new shares, and the Shares will remain primarily listed and traded on the Hong Kong Stock Exchange.

The Company has confidentially submitted an application to the SGX-ST regarding the Proposed Secondary Listing. As of this announcement, the Company has not yet received the eligibility-to-list letter (“ETL”) from the SGX-ST concerning the Proposed Secondary Listing.

On June 24, 2025, the Company received notification from the China Securities Regulatory Commission (“CSRC”) regarding the filing for the Proposed Secondary Listing for overseas issuance and listing.

The Directors believe that a secondary listing on the SGX-ST would allow the Group to attract investment funds focused on the Asia-Pacific region and local capital within Southeast Asia, thus improving the shareholder structure. Furthermore, it anticipates a greater impact on the Group’s business development within Southeast Asia and the Middle East. The Group has already established Singapore as its regional headquarters for its Southeast Asia and Middle East operations, incorporating companies in Singapore that span the entire pharmaceutical value chain, including R&D, manufacturing, commercialization, and investment. These include CMS R&D as an international independent R&D company, PharmaGend as a pharmaceutical manufacturing CMO/CDMO company, Rxilient as a pharmaceutical development, registration, and commercialization company, and Singapore Venture Capital as an industrial investment company. The collaboration of these companies aims to provide Southeast Asian patients with more high-quality, affordable treatment options, contribute to the pharmaceutical industry chain’s development in Southeast Asia, strengthen the Group’s global reputation and market position, advance the Group’s “Glocalization” strategy, and foster additional growth for the Group.

The Company will release further announcements concerning the Proposed Secondary Listing as needed, in compliance with relevant laws and regulations.

The Proposed Secondary Listing depends on the SGX-ST granting an ETL and the fulfillment of any conditions specified within the ETL. Consequently, there is no guarantee that the Proposed Secondary Listing will be completed. Shareholders and potential investors are advised to exercise caution when trading the Company’s securities.

About CMS
CMS operates as a platform, connecting pharmaceutical innovation and commercialization with strong product lifecycle management capabilities. Its focus is to deliver competitive products and services that address unmet medical needs.

CMS prioritizes global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently advances the clinical research, development, and commercialization of these products. This enables the continuous translation of scientific research into clinical practices for the benefit of patients.

CMS is deeply involved in several specialty therapeutic areas and has developed proven commercialization capabilities, extensive networks, and expert resources, resulting in leading academic and market positions for its major marketed products. CMS is committed to furthering the development of its key specialty fields and expanding its business scope. While strengthening its cardio-cerebrovascular/gastroenterology business, CMS independently manages its skin health and ophthalmology businesses, with the goal of achieving leading positions in these specialty therapeutic areas, while enhancing scale and efficiency. Simultaneously, CMS has extended its business into the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies entering Southeast Asia, further supporting the Group’s sustainable and healthy development.

CMS Disclaimer and Forward-Looking Statements
This press release is not intended as a product promotion and is not for advertising purposes. It does not recommend any drugs, medical devices, or indications. For information regarding the diagnosis and treatment of specific diseases, please consult with your doctor or other healthcare professionals. Treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release, prepared by CMS, does not constitute an offer to purchase or subscribe for any securities, nor shall it form the basis of or be relied upon in connection with any contract or binding commitment. CMS has prepared this press release based on information and data it deems reliable, but makes no express or implied representation or warranty regarding the truth, accuracy, completeness, fairness, or reasonableness of the contents. Certain topics discussed may include forward-looking statements regarding the Group’s market opportunity and business prospects. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. The Group does not adopt any forward-looking statements and projections made by third parties included in this press release, and the Company is not responsible for such statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email:

Website:

Source: China Medical System Holdings Ltd.

“`